US Patent 7,183,282 Scope and Claims Analysis and Patent Landscape for the Covered Compounds and Formulations
US Patent 7,183,282 is directed to (i) specific chemical compounds (and their pharmaceutically acceptable salts) defined by a formula recited in the independent claims, and (ii) pharmaceutical compositions that contain the claimed compound plus at least one pharmaceutically acceptable carrier or diluent. The claim set shown is limited to two compound claims and two composition claims.
The analysis below focuses on claim scope using the only claim language provided (formula-defined compound; salt variants; compositions defined by carrier/diluent). The provided excerpt does not include the formula text itself, nor does it include claim dependencies, definitions, examples, or specification-based interpretive anchors.
What is US Patent 7,183,282 claim 1 scope and what compounds does it cover?
Claim 1 scope (as provided):
“a compound or a pharmaceutically acceptable salt form thereof according to the following formula”
Key scope drivers
-
Formula-defined structural limitation is the core boundary.
Claim 1 is not a genus defined by functional properties. It is a “according to the following formula” claim. In US claim construction, that typically means the patent’s practical coverage tracks the exact scaffold and substituent pattern spelled out in the formula in the claim text.
-
Salts are included without changing the core structure.
The phrase “pharmaceutically acceptable salt form thereof” expands coverage to salt forms of the same underlying compound defined by the formula. Practically, that can matter for infringement because many competitors sell the same free base as a salt (or vice versa), and both can fall within the same claim if the salt is “pharmaceutically acceptable.”
-
No other restrictions are expressed in claim 1 excerpt.
The excerpt does not specify stereochemistry (unless it appears in the formula), polymorph, particle size, route of synthesis, dosage, or therapeutic use. If those elements appear in the formula, they may be present indirectly. If they do not appear, claim 1 does not impose them.
What claim 1 does not cover (based on provided claim excerpt)
- It does not claim a method of treating a disease, because no method-of-use language appears in the provided claims.
- It does not claim a specific dosage form beyond a generic “pharmaceutical composition” in claims 3–4.
- It does not claim a manufacturing method.
How do formula-based compound claims usually get construed for infringement risk?
For formula-based claims, the infringement test typically turns on whether an accused compound contains the structural elements required by the claimed formula. For salts, courts often look at whether the marketed product is actually a salt of the claimed compound and whether it qualifies as “pharmaceutically acceptable” under ordinary meaning and specification support.
What is US Patent 7,183,282 claim 2 scope and how is it different from claim 1?
Claim 2 scope (as provided):
“a compound or a pharmaceutically acceptable salt form thereof according to the following formula”
Claim 2 is structurally another formula-defined compound claim. The excerpt shows two separate formula references for claims 1 and 2, but it does not show whether the formula in claim 2 is:
- a different scaffold,
- the same scaffold with different substituents,
- a narrower subset,
- or a different stereochemical or ring-closure variant.
Because the formula text is not included in the prompt, the only definitive conclusion is that claim 2 independently covers a second formula-defined compound set (including salts) as written in the claims.
Claim strategy inference from having parallel formula claims
Having two compound claims with separate formula blocks is commonly used to secure distinct chemical coverage within one patent family, often to capture:
- a primary scaffold and a secondary variant,
- or two closely related sets of analogs.
In litigation, that structure supports an argument that the patent has multiple independent “entry points” for infringement, depending on which compound set is practiced by a challenger.
What compositions are covered by US Patent 7,183,282 claims 3 and 4?
Claim 3 scope (as provided):
“a pharmaceutical composition, comprising: the compound according to claim 1; and at least one pharmaceutically acceptable carrier or diluent.”
Claim 4 scope (as provided):
“a pharmaceutical composition, comprising: the compound according to claim 2; and at least one pharmaceutically acceptable carrier or diluent.”
Key scope drivers
-
Composition is defined by inclusion, not by formulation parameters.
Claims 3 and 4 require only:
- the claimed compound (from claim 1 or 2), and
- a pharmaceutically acceptable carrier or diluent.
The excerpt does not specify:
- oral versus injectable,
- solid versus liquid,
- release profile,
- excipient identity,
- or dose regimen.
As a result, these composition claims are broad in the way they are drafted: they can read on many dosage forms as long as they contain the claimed compound in a pharmaceutical composition.
-
Carrier/diluent language expands beyond the active ingredient.
The carrier or diluent element is flexible. In infringement analysis, a generic manufacturer that uses any standard pharmaceutically acceptable excipient system still tends to satisfy this element, provided the compound itself meets claim 1 or claim 2.
-
No dosage form limitations in the provided claims.
A dosage form that is different from the examples in the specification can still infringe because claim language is generic. Unless the formula or specification adds implicit limits, the plain claim text points to broad coverage.
Where formulation patents typically narrow compared with US 7,183,282
A typical formulation patent narrows with:
- specific excipient systems,
- specific particle size,
- solid-state forms (polymorphs),
- coating compositions,
- or controlled-release mechanisms.
This patent excerpt does not show those limiting elements. That typically makes claims 3–4 easier to satisfy if an accused product includes the claimed compound.
How many independent claim “entry points” does US 7,183,282 provide?
From the provided text, there are two independent compound claims (claims 1 and 2) and two independent composition claims (claims 3 and 4). There are no additional independent claim types shown (method-of-use, device, dosing, or process).
Practical effect: a competitor can attempt to avoid infringement by:
- choosing a chemical structure that does not fall within either formula block, or
- selling a salt/free-base form that is argued not to be a pharmaceutically acceptable salt (rarely effective if salts are acknowledged and the salt is standard), or
- avoiding formulation as a “pharmaceutical composition” (also rarely realistic because most drug products are formulated for administration).
What patent landscape risks exist for generics and salt/formulation variants around US 7,183,282?
Because the claims shown are broad (formula + salts; compositions with standard carriers), the main landscape risks are:
-
Salt switching does not necessarily design around.
If the active ingredient is the same formula compound in another salt form, claims 1–2 explicitly include “pharmaceutically acceptable salts.” A design-around needs a different structural compound rather than a mere salt selection.
-
Formulation changes do not remove exposure.
Claims 3–4 do not restrict excipients, dosage form, or route. Standard formulation work generally does not avoid infringement if the active is within claim 1 or claim 2.
-
If a competitor targets a different stereoisomer or polymorph, impact depends on whether the formula requires it.
If the formula encodes stereochemistry or specific ring structures, then a different stereoisomer may fall outside. If the formula does not specify stereochemistry, it may still cover all stereochemical forms unless the specification limits claim interpretation.
-
Regulatory entry strategy may still trigger patent infringement risk.
Even when patents do not contain method-of-use claims, a competitor can trigger an “artificial infringement” theory under Hatch-Waxman for submission activities (Paragraph IV) if the proposed generic product contains the claimed active compound.
How strong is the patent estate implied by the claim types in US 7,183,282?
Based strictly on the claim excerpt:
- The compound claims are likely core active-ingredient patents because they are formula-defined and not limited to a specific use.
- The composition claims likely provide secondary coverage that can capture many downstream drug product presentations.
But strength cannot be fully assessed from claim excerpts alone because enforceability also depends on:
- how broadly or narrowly the formula is defined in the full claim,
- claim definiteness and antecedent basis,
- novelty and non-obviousness over prior art,
- prosecution history,
- and whether the formula definitions align with enablement and written description.
No litigation record or prosecution history is included in the prompt, so landscape strength can only be assessed as “broad claim coverage style,” not as “litigation-grade enforceability.”
What does US 7,183,282 likely mean for Paragraph IV challenges?
Likely paragraph IV attack surfaces
- If the generic’s proposed active compound matches the formula in claim 1 or claim 2, the most direct challenge is invalidity (anticipation/obviousness) or noninfringement on structure.
- If the generic uses a different scaffold not covered by either formula, the challenge may be resolved on noninfringement without reaching validity.
Likely outcomes if the generic includes the same compound
- A narrow formula difference can still drive a noninfringement argument.
- If the compound is the same active in a different salt, claims 1–2 are structured to still capture it, making invalidity a common litigation path.
What generic entry risks exist if a competitor launches a product containing the same active as US 7,183,282?
The risks are primarily tied to whether the competitor’s marketed drug:
- Contains a compound that fits the formula in claim 1 or claim 2 (including required substituents and any stereochemical elements inside the formula).
- Is sold as a pharmaceutical composition containing the compound with pharmaceutically acceptable carriers/diluents.
Because claims 3–4 are composition claims defined broadly, a product launch with the same active ingredient almost always lands within their scope if the active falls within claim 1 or 2.
What competitor product design-around paths are suggested by the claim structure?
Within the boundaries of the claim excerpt, design-around is most plausibly achieved by:
-
Switching to a structurally distinct active ingredient not covered by either formula.
This is the most robust route because it attacks the inclusion element of claims 1–2 and 3–4.
-
If stereochemistry is encoded in the formula: switching to the non-covered stereoisomer.
This depends on whether the formula in claim 1 or 2 includes stereochemical markers.
-
Salt selection alone is likely insufficient.
The claims expressly include pharmaceutically acceptable salt forms.
-
Formulation excipient changes alone are likely insufficient.
The claims require only “at least one pharmaceutically acceptable carrier or diluent.”
Key claim chart (based only on the provided claim excerpt)
| Patent |
Claim |
Coverage element |
Scope limitation in excerpt |
Main infringement hook |
| US 7,183,282 |
1 |
Compound/salt |
“according to the following formula” |
Accused compound matches formula; salt is pharmaceutically acceptable |
| US 7,183,282 |
2 |
Compound/salt |
“according to the following formula” (second formula) |
Matches formula 2; salt is pharmaceutically acceptable |
| US 7,183,282 |
3 |
Pharmaceutical composition |
Contains claim 1 compound + pharmaceutically acceptable carrier/diluent |
Accused drug product includes claim 1 active in any standard pharm composition |
| US 7,183,282 |
4 |
Pharmaceutical composition |
Contains claim 2 compound + pharmaceutically acceptable carrier/diluent |
Accused drug product includes claim 2 active in any standard pharm composition |
Key Takeaways
- US 7,183,282 is structured around formula-defined compound coverage (claims 1–2) plus broad pharmaceutical composition coverage (claims 3–4) that add only a pharmaceutically acceptable carrier or diluent.
- The claims shown are not use-limited and, based on the excerpt, are not dosage-form limited, which typically increases the probability that product formulation changes will not avoid infringement if the active falls within the claimed formulas.
- Salt switching is expressly covered via “pharmaceutically acceptable salt form,” so design-around is more likely to require a structurally distinct compound rather than a salt or excipient change.
FAQs
1) Does US 7,183,282 protect only the active ingredient or also the drug product?
It protects both: claims 1–2 cover compounds/salts, and claims 3–4 cover pharmaceutical compositions containing those compounds with pharmaceutically acceptable carriers or diluents.
2) Can a generic avoid infringement by selling a different salt of the same compound?
If the salt is “pharmaceutically acceptable” and the underlying compound matches claim 1 or claim 2’s formula, the excerpted claims still capture it.
3) Are the composition claims limited to a specific dosage form (tablet, capsule, injection)?
The provided claim language does not specify dosage form. It only requires a pharmaceutical composition containing the claimed compound plus a pharmaceutically acceptable carrier or diluent.
4) Are method-of-use patents part of the claim set shown for US 7,183,282?
No method-of-use claims are shown in the provided excerpt. The excerpt contains compound and composition claims only.
5) What is the most direct noninfringement approach for competitors?
Using an active ingredient whose structure does not fall within either formula recited in claims 1 or 2.
References
- US Patent 7,183,282. United States Patent and Trademark Office. (Claim text as provided in prompt).
